title: Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?
authors.affiliation: Hacettepe University Cancer Institute, Ankara, Turkey.
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000077341:Lapatinib; D011799:Quinazolines / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D000068878:Trastuzumab / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069287:Capecitabine; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C485206:pertuzumab